
Boehringer Ingelheim Opens $31.5 Million Oncology Antibody-Drug Conjugate Facility in Switzerland
Boehringer Ingelheim announced the official opening of a new antibody-drug conjugate (ADC) research and development facility in Basel, Switzerland, through its wholly owned subsidiary, NBE Therapeutics. According to the company, the $31.5 million facility …